Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
PRLD - Prelude Therapeutics Inc
$74.18
-0.99(-1.32%)8:59:51 PM 1/15/2021
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Stock news

    01/11/2021PRLD
    Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 375,000 shares of its vo...

    01/7/2021PRLD
    Prelude Therapeutics Announces Pricing of Upsized Public Offering

    WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 milli...

    01/4/2021PRLD
    Prelude Therapeutics Announces Launch of Proposed Public Offering

    WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the...

    12/25/2020PRLD
    Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

    12/16/2020PRLD
    Is PRLD A Good Stock To Buy Now?

    With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Prelude Therapeutics Incorporated (NASDAQ:PRLD). Is PRLD a good stock to […]

    11/10/2020PRLD
    Prelude Therapeutics Announces Third Quarter 2020 Financial Results

    \- Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M - \- Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 -\- Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of PRT543 -WILMINGTON, Del., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”, “the Company”, “we”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its f...

    10/3/2020PRLD
    Metacrine, Prelude Therapeutics See Activist Action

    New Enterprise Associates revealed a large investment in biopharmaceutical company Metacrine. Baker Brothers Advisors disclosed an initial position in oncology-focused biopharmaceutical firm of Prelude.